KLIFO, Europe’s largest independent provider of clinical trial supply packaging and distribution, has officially received manufacturing and importation authorization from the Danish Medicines Agency for its new 65,000 sq ft Abildager facility in Copenhagen.
A Major Milestone
The authorization marks a key step in KLIFO’s growth, enabling the company to deliver flexible, sustainable, and innovative clinical supply solutions to the pharmaceutical and biotech sectors.
State-of-the-Art Capabilities
The purpose-built facility is designed for end-to-end clinical trial support, including:
- Expanded capacity to serve studies from small-scale trials to global Phase III and post-marketing programs.
- Comprehensive temperature management from controlled room temperature to -80°C, plus light-sensitive product handling.
- Primary and secondary packaging and global distribution capabilities.
“Approval of our new facility represents a major step forward for KLIFO. It’s already attracting Nordic and international clients, cementing Copenhagen as a leading life science hub,”
- René Pedersen, CEO, KLIFO.
Accelerating Global Trials
With this new site, combined with KLIFO’s experienced team, international reach, and compliance expertise, the company can:
- Speed up project setup
- Reduce turnaround times
- Minimize clinical supply chain challenges
KLIFO remains the largest independent end-to-end clinical trial supply services provider in Europe, offering proactive management across the full supply and logistics process.
